Comprehensive Analysis of Off-target and On-target Effects Resulting from Liver-directed CRISPR-Cas9-mediated Gene Targeting with AAV Vectors

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2024 Dec 10

PMID 39655309

Authors

Kshitiz Singh

Raffaele Fronza

Hanneke Evens

Marinee K Chuah

Thierry VandenDriessche

Affiliations

Soon will be listed here.

Abstract

Comprehensive genome-wide studies are needed to assess the consequences of adeno-associated virus (AAV) vector-mediated gene editing. We evaluated CRISPR-Cas-mediated on-target and off-target effects and examined the integration of the AAV vectors employed to deliver the CRISPR-Cas components to neonatal mice livers. The guide RNA (gRNA) was specifically designed to target the factor IX gene (F9). On-target and off-target insertions/deletions were examined by whole-genome sequencing (WGS). Efficient F9-targeting (36.45% ± 18.29%) was apparent, whereas off-target events were rare or below the WGS detection limit since only one single putative insertion was detected out of 118 reads, based on >100 computationally predicted off-target sites. AAV integrations were identified by WGS and shearing extension primer tag selection ligation-mediated PCR (S-EPTS/LM-PCR) and occurred preferentially in CRISPR-Cas9-induced double-strand DNA breaks in the F9 locus. In contrast, AAV integrations outside F9 were not in proximity to any of ∼5,000 putative computationally predicted off-target sites (median distance of 70 kb). Moreover, without relying on such off-target prediction algorithms, analysis of DNA sequences close to AAV integrations outside the F9 locus revealed no homology to the F9-specific gRNA. This study supports the use of S-EPTS/LM-PCR for direct comprehensive, sensitive, and unbiased off-target analysis.

References

Miller D, Petek L, Russell D . Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol. 2003; 23(10):3550-7. PMC: 164770. DOI: 10.1128/MCB.23.10.3550-3557.2003. View

Mali P, Yang L, Esvelt K, Aach J, Guell M, DiCarlo J . RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823-6. PMC: 3712628. DOI: 10.1126/science.1232033. View

Li N, Gou S, Wang J, Zhang Q, Huang X, Xie J . CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I. Mol Ther. 2020; 29(3):1001-1015. PMC: 7934638. DOI: 10.1016/j.ymthe.2020.11.023. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Pattanayak V, Lin S, Guilinger J, Ma E, Doudna J, Liu D . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013; 31(9):839-43. PMC: 3782611. DOI: 10.1038/nbt.2673. View

Nair N, Rincon M, Evens H, Sarcar S, Dastidar S, Samara-Kuko E . Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood. 2014; 123(20):3195-9. PMC: 4023424. DOI: 10.1182/blood-2013-10-534032. View

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

Yaish O, Asif M, Orenstein Y . A systematic evaluation of data processing and problem formulation of CRISPR off-target site prediction. Brief Bioinform. 2022; 23(5). DOI: 10.1093/bib/bbac157. View

Rose J, Popp N, Richardson C, Stephany J, Mathieu J, Wei C . Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. Nat Commun. 2020; 11(1):2697. PMC: 7264211. DOI: 10.1038/s41467-020-16542-9. View

10.

Afzal S, Wilkening S, von Kalle C, Schmidt M, Fronza R . GENE-IS: Time-Efficient and Accurate Analysis of Viral Integration Events in Large-Scale Gene Therapy Data. Mol Ther Nucleic Acids. 2017; 6:133-139. PMC: 5363413. DOI: 10.1016/j.omtn.2016.12.001. View

11.

Nakai H, Montini E, Fuess S, Storm T, Grompe M, Kay M . AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003; 34(3):297-302. DOI: 10.1038/ng1179. View

12.

Ghodsi M, Liu B, Pop M . DNACLUST: accurate and efficient clustering of phylogenetic marker genes. BMC Bioinformatics. 2011; 12:271. PMC: 3213679. DOI: 10.1186/1471-2105-12-271. View

13.

Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z . High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016; 529(7587):490-5. PMC: 4851738. DOI: 10.1038/nature16526. View

14.

Chandler R, LaFave M, Varshney G, Trivedi N, Carrillo-Carrasco N, Senac J . Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015; 125(2):870-80. PMC: 4319425. DOI: 10.1172/JCI79213. View

15.

Nobles C, Reddy S, Salas-Mckee J, Liu X, June C, Melenhorst J . iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome Biol. 2019; 20(1):14. PMC: 6337799. DOI: 10.1186/s13059-019-1625-3. View

16.

Singh K, Evens H, Nair N, Rincon M, Sarcar S, Samara-Kuko E . Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9. Mol Ther. 2018; 26(5):1241-1254. PMC: 5993986. DOI: 10.1016/j.ymthe.2018.02.023. View

17.

Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P . Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther. 2012; 20(6):1177-86. PMC: 3369298. DOI: 10.1038/mt.2012.47. View

18.

Schubert M, Thommandru B, Woodley J, Turk R, Yan S, Kurgan G . Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci Rep. 2021; 11(1):19482. PMC: 8484621. DOI: 10.1038/s41598-021-98965-y. View

19.

Fu Y, Dai X, Wang W, Yang Z, Zhao J, Zhang J . Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res. 2021; 49(2):969-985. PMC: 7826255. DOI: 10.1093/nar/gkaa1251. View

20.

Nutter L, Heaney J, Lloyd K, Murray S, Seavitt J, Skarnes W . Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo". Nat Methods. 2018; 15(4):235-236. DOI: 10.1038/nmeth.4559. View